trending Market Intelligence /marketintelligence/en/news-insights/trending/ky33cscfvcc4l-5iz7gwsa2 content esgSubNav
In This List

Gilead Sciences' chief scientific officer to step down; replacement named

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Gilead Sciences' chief scientific officer to step down; replacement named

Gilead Sciences Inc. said Norbert Bischofberger is stepping down as the company's chief scientific officer and executive vice president of research and development, effective at the end of April.

Bischofberger joined the biopharmaceutical company in 1990, has held the executive vice president role since 2000 and became the chief scientific officer in 2007. He will stay with Gilead Sciences until July.

John McHutchison will replace Bischofberger as chief scientific officer. McHutchison will be responsible for the company's R&D organization. He is serving as Gilead's executive vice president of clinical research.

The company has also appointed Andrew Cheng as chief medical officer, effective in April. Cheng is Gilead's executive vice president of clinical R&D operations.